Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0038358 (gastric ulcer)
 5,179 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The potentially damaging gastric and duodenal effects of dipyrone, a nonnarcotic analgesic agent, were evaluated in three phases in comparison to placebo and paracetamol. Three groups of 12 healthy adult volunteers were treated in a double-blind study, according to a cross-over, randomization sequence, using the double-dummy technique, for two 15-day periods, with dipyrone 3 g/day and placebo (group I), dipyrone 1.5 g/day and placebo (group II), and dipyrone 1.5 g/day and paracetamol 1.5 g/day (group III). An esophagogastroduodenoscopy was performed at the beginning and end of each treatment period. In the first treatment group, grade-3 and 4 mucosal lesions were found after dipyrone administration (3 g/day) in 3 of 12 (25%) subjects (multiple antral erosions, gastric ulcer and duodenal ulcer, 1 case each), whereas grade-2 mucosal lesions (antral erosions) were detected in 1 of 12 cases (8%) after the corresponding placebo treatment. The difference between the two treatments, however, was not statistically significant (p > 0.05). Only in the gastric ulcer case were subjective symptoms reported (feeling of hunger). At the 1.5-g/day dose (groups II and III), dipyrone produced no gastroduodenal lesions, the endoscopic results showing no appreciable difference between dipyrone and either placebo (p = 0.54) or paracetamol (p = 0.99). No subjective symptoms were reported in any of these subjects. Dipyrone, administered for 2 weeks, has effects on the gastric and duodenal mucosa comparable to those of paracetamol and placebo, though noticeable damage is detectable at a dosage of 3 g/day.
 ...
PMID:Endoscopic assessment of the effects of dipyrone (metamizol) in comparison to paracetamol and placebo on the gastric and duodenal mucosa of healthy adult volunteers. 873 93

Examination has been carried out on 34 young men (average age: 22 years) with chronic erosive gastritis. Chronic erosions were situated most frequently in the prepyloric part of the stomach (88.2%). Duodenal ulcer-was found in 14 patients (41.1%), gastric ulcer was found in 1 patient (2.9%). In 19 examined patients (56.0%) chronic erosive gastritis existed without any other disease of the gastrointestinal tract. Clinical picture, gastric secretion and histopatological examination were compared in two group: I-chronic erosive gastritis without any other changes within the gastrointestinal tract and group II-chronic erosive gastritis coexisting with duodenal ulcer in the clinical picture of the group I, pain usually occurred after a meal and was felt as a heaviness sensation in epigastrum, while in the group II patients felt suction, hunger pain night pain and heartburn. Gastric secretion in the two group did not differ much. Microscopic examination of the mucosa usually confirmed chronic active gastritis. A typical feature for both group was regenerative glandular hyperplasia of the gastric mucosa. Despite many common features, it is impossible to identify explicitly and univocally the relationship between chronic erosive gastritis and ulceration.
 ...
PMID:[Chronic gastritis and ulcer disease in young men]. 909 50